Considerable strength remains visible among biotechnology stocks, as reflected by the 1.8 percent gain being posted by the iShares NASDAQ Biotechnology Index yesterday.
In biotech, knowing the competition is integral to understanding how drugs will succeed once they are on the market. Below, analysts weigh in …
Analyst Ritu Baral of Cowen & Co was out today with research notes on drug makers Sarepta Therapeutics Inc (NASDAQ:SRPT) and Cempra Inc (NASDAQ:CEMP), discussing the FDA …
Alibaba Group Holding Ltd (NYSE:BABA) is down 2% in pre-market down to $79.30 after the Chinese e-commerce company disclosed an SEC investigation last …
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, announced that the U.S.
Sarepta Therapeutics Inc (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today reported financial results for the three months ended March 31, 2016, and provided …
Valeant Pharmaceuticals Intl Inc Mizuho Securities analyst Irina Rivkind Koffler is one of Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s biggest bears, but she is also …
Heading into the May 26 PDUFA date for an approval or nonapproval of Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Duchenne muscular dystrophy treatment, eteplirsen, WBB Securities …
The ups and downs of biotech companies cease to abate as analysts weigh in on Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Celgene Corporation (NASDAQ:CELG), …
Healthcare analysts are weighing in today on biopharmaceutical companies Sarepta Therapeutics Inc (NASDAQ:SRPT) and Catalyst Pharmaceuticals Inc (NASDAQ:CPRX), as shares of both companies fell …
